Cosmo Pharmaceuticals N.V.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Cosmo Pharmaceuticals N.V.
Mersana signs its third ADC partnership with big pharmas for the year with Merck agreement. Lilly expands its RNA editing partnership with ProQR, which now has the potential to earn an additional $2.5bn. Novartis continues its divestment efforts in deals with Harrow, Erasca.
Private Company Edition: The global accelerator has new commitments from HHS and the Wellcome Trust. Also, Apollo buys into Sofinnova Partners with an up to €1bn investment, Castle Creek raised $124.6m in private funding this year in lieu of an IPO and Remix closed a $70m series B round.
Licensing deals and partnerships carried the day during another hectic J.P. Morgan Healthcare Conference. Pfizer racked up its third deal of the week in a cancer collaboration with Dren Bio.
Digital Health Roundup, April 2021: Digital Transformation In OR, Clinical Trials, Remote Monitoring
In this new roundup feature focusing on the most notable developments in digital health, we pick the key news from April.
- Specialty Pharmaceuticals
- Controlled Release
- Other Names / Subsidiaries
- Aries Group, Ltd
- Aries Pharmaceuticals, Inc.
- Cosmo Technologies Limited
- Cosmo Pharmaceuticals S.p.A.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.